A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

QR Code

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

Ernie Anand,1 Lovisa Berggren,2 Claudia Deix,3 Ágoston Tóth,4 David P McDonnell5 1Neuroscience Medical Affairs – EU, Eli Lilly, Windlesham, United Kingdom; 2Global Statistical Sciences, Lilly Deutschland GmbH, Bad Homburg, Germany; 3Neuroscience, Eli Lilly Regional O...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	An, E, Berggren L, Deix C, Tóth Á, McDonnell DP
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2015
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/8d5b267f3f554425b7cf329f8a710e0c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
par: Ciudad A, et autres
Publié: (2013)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
par: Ascher-Svanum H, et autres
Publié: (2014)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
par: Rosaria Di Lorenzo, et autres
Publié: (2010)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
par: Adel Gabriel
Publié: (2010)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
par: Katagiri H, et autres
Publié: (2018)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
par: Anand E, et autres
Publié: (2016)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
par: JP Lindenmayer
Publié: (2010)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
par: Citrome L, et autres
Publié: (2019)

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
par: Katagiri H, et autres
Publié: (2018)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
par: Wani RA, et autres
Publié: (2015)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
par: Dhiren Singh, et autres
Publié: (2009)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
par: Wani RA, et autres
Publié: (2015)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
par: Iyo M, et autres
Publié: (2021)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
par: Suzuki H, et autres
Publié: (2013)

Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
par: Inada K, et autres
Publié: (2020)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
par: Louz&atilde; M, et autres
Publié: (2011)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
par: Si TM, et autres
Publié: (2015)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
par: Yang F, et autres
Publié: (2018)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
par: Liang Y, et autres
Publié: (2017)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
par: Natalia N. Petrova, et autres
Publié: (2020)

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia
par: Hirano J, et autres
Publié: (2013)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
par: Zhao Y, et autres
Publié: (2013)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2019)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
par: Pietrini F, et autres
Publié: (2019)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
par: De Hert M, et autres
Publié: (2015)

EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
par: I. V. Shirinsky, et autres
Publié: (2014)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
par: &Uuml;nsal C, et autres
Publié: (2013)

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
par: Strzelecki D, et autres
Publié: (2015)

Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
par: Nguyen L, et autres
Publié: (2015)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
par: Montemagni C, et autres
Publié: (2016)

Risperidone long-acting injection: a review of its long term safety and efficacy
par: Michael K Rainer
Publié: (2008)

Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
par: Takeshima M, et autres
Publié: (2018)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
par: Chen CY, et autres
Publié: (2018)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
par: Gao K, et autres
Publié: (2013)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
par: Zhang H, et autres
Publié: (2016)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
par: Berman R, et autres
Publié: (2011)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
par: Takahashi M, et autres
Publié: (2012)